1 Harbord M, "The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease" 10 : 239-254, 2016
2 Sehgal P, "Systematic review : safety of mesalazine in ulcerative colitis" 47 : 1597-1609, 2018
3 Green JR, "Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis : a 3-year prospective observational study" 19 : 435-442, 2004
4 Haq MI, "Mesalazine-induced cardiotoxicity" 4 : 24-, 2019
5 Raine T, "ECCO guidelines on therapeutics in ulcerative colitis : medical treatment" 16 : 2-17, 2022
6 Bunu DM, "Cardiovascular manifestations of inflammatory bowel disease : pathogenesis, diagnosis, and preventive strategies" 2019 : 3012509-, 2019
7 Robertson E, "Balsalazide-induced myocarditis" 130 : e121-e122, 2008
8 Patil SA, "Balsalazide disodium for the treatment of ulcerative colitis" 2 : 177-184, 2008
1 Harbord M, "The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease" 10 : 239-254, 2016
2 Sehgal P, "Systematic review : safety of mesalazine in ulcerative colitis" 47 : 1597-1609, 2018
3 Green JR, "Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis : a 3-year prospective observational study" 19 : 435-442, 2004
4 Haq MI, "Mesalazine-induced cardiotoxicity" 4 : 24-, 2019
5 Raine T, "ECCO guidelines on therapeutics in ulcerative colitis : medical treatment" 16 : 2-17, 2022
6 Bunu DM, "Cardiovascular manifestations of inflammatory bowel disease : pathogenesis, diagnosis, and preventive strategies" 2019 : 3012509-, 2019
7 Robertson E, "Balsalazide-induced myocarditis" 130 : e121-e122, 2008
8 Patil SA, "Balsalazide disodium for the treatment of ulcerative colitis" 2 : 177-184, 2008